Skip to Main Content

An inhaled mRNA-based treatment for patients with cystic fibrosis from Translate Bio failed to produce meaningful improvements in lung function, the company said Wednesday.

The new clinical trial results, while still preliminary, are a setback for Translate’s effort to develop its first drug based on messenger RNA — the same protein-making technology powering a pair of effective Covid-19 vaccines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED